TY - JOUR T1 - Selection of chemotherapy for patients with advanced non–small cell lung cancer JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - S46 LP - S50 DO - 10.3949/ccjm.78.s2.10 VL - 79 IS - 5 e-suppl 1 AU - Nathan A. Pennell Y1 - 2012/05/01 UR - http://www.ccjm.org/content/79/5_e-suppl_1/S46.abstract N2 - Chemotherapy remains the first-line treatment for most patients with stage IV non–small cell lung cancer (NSCLC), but optimal regimens are now defined by histology. Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. Maintenance therapy is emerging as a treatment strategy for patients who do not progress after four cycles of first-line chemotherapy. In the maintenance setting, pemetrexed and erlotinib significantly prolong overall survival compared with placebo after the completion of first-line chemotherapy. ER -